98%
921
2 minutes
20
The etiology of intellectual disabilities (ID) remains unknown for the majority of patients. Due to reduced reproductive fitness in many individuals with ID, de novo mutations account for a significant portion of severe ID. The ATP-dependent SWI/SNF chromatin modifier has been linked with neurodevelopmental disorders including ID and autism. ARID2 is an intrinsic component of polybromo-associated BAF (PBAF), the SWI/SNF subcomplex. In this study, we used clinical whole exome sequencing (WES) in proband-parent-trios to identify the etiology of ID. We identified four independent, novel, loss of function variants in ARID2 gene in four patients, three of which were confirmed to be de novo. The patients all have ID and share other clinical characteristics including attention deficit hyperactivity disorder, short stature, dysmorphic facial features, and Wormian bones. All four novel variants are predicted to lead to a premature termination with the loss of the two conservative zinc finger motifs. This is the first report of mutations in ARID2 associated with developmental delay and ID.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10048-015-0454-0 | DOI Listing |
J Cancer Res Clin Oncol
August 2025
Department of Medical Oncology, Mie University Hospital, 2-174, Tsu, 514- 8507, Mie, Japan.
Purpose: The estimation of the primary site is crucial when considering chemotherapy regimens in cancer of unknown primary (CUP). The task is particularly challenging for poorly differentiated or undifferentiated carcinoma, or unknown histological tumors with unknown primary (U-CUP). Instead of site-specific chemotherapy, a biomarker-guided therapy using genomic testing is required to predict the efficacy of molecular-targeted agents and immune checkpoint inhibitors (ICI).
View Article and Find Full Text PDFMod Pathol
June 2025
Department of Translational Molecular Pathology, MD Anderson Cancer Center, The University of Texas, Houston, Texas; Department of Genomic Medicine, MD Anderson Cancer Center, The University of Texas, Houston, Texas. Electronic address:
Gallbladder carcinoma is a deadly disease with a poor prognosis, and recent clinical data suggest only a modest benefit of PD1/PDL1 inhibitors in this disease. Optimizing immunotherapeutic approaches will require a detailed understanding of the immunogenomic landscape of this disease worldwide. We combined targeted next-generation sequencing and immunohistochemistry to create detailed immunogenomic landscapes from 2 cohorts of gallbladder cancer cases from the United States (n = 60) and Chile (n = 62).
View Article and Find Full Text PDFDiscov Oncol
June 2025
Department of Hematology, Children's Hospital of Nanjing Medical University, No. 72 Guangzhou Road, Nanjing, 210008, China.
The co-occurrence of rhabdomyosarcoma (RMS) and B-cell acute lymphoblastic leukemia (B-ALL) has been rarely reported, and the shared molecular drivers remain unidentified. This case report describes a pediatric patient diagnosed with both malignancies simultaneously. Whole exome sequencing of RMS and B-ALL samples from this patient identified 91 shared somatic mutations.
View Article and Find Full Text PDFBiomed Rep
July 2025
Department of Anatomy, Faculty of Medical Science, Naresuan University, Phitsanulok 65000, Thailand.
The SWitch/sucrose non-fermentable chromatin remodeling complex functions as a tumor suppressor by regulating gene expression and thus various cellular processes. Key subunits of this complex, including the AT-rich interactive domain (ARID)-containing proteins ARID1A, ARID1B and ARID2, are frequently mutated in cancer, including colorectal cancer (CRC). However, their protein expression and prognostic significance in CRC remain unclear.
View Article and Find Full Text PDFHepatol Res
August 2025
Department of Gastroenterology and Hepatology, Institute of Science Tokyo, Tokyo, Japan.
Aim: The mechanism of hepatocarcinogenesis after sustained virological response (SVR) in hepatitis C virus (HCV) patients is unclear. We compared gene profiles of hepatocellular carcinoma (HCC) between HCV-SVR, steatotic liver disease (SLD), and HCV-non-SVR patients.
Methods: This study analyzed 126 resected HCCs from patients with HCV and SLD, classifying them as HCV-SVR (n = 22), HCV-non-SVR (n = 56), and SLD (n = 48).